Emcure Pharmaceuticals Ltd. (BSE: 544210, NSE: EMCURE) has launched Poviztra®, a semaglutide injection, for weight management across India. Poviztra® is available in a once-weekly pen device and is priced starting at ₹8790/- per month. Emcure is the first Indian company to exclusively distribute and commercialise Poviztra®. The product supports chronic weight management in adults with obesity or overweight and reduces cardiovascular event risks.
Poviztra® Launch Details
Emcure Pharmaceuticals Ltd. has announced the commercial launch of Poviztra®, a semaglutide injection intended for weight management, throughout India. This makes Emcure the first Indian company with exclusive distribution and commercialisation rights for Poviztra®. This launch was announced on December 22, 2025.
Product Overview
Poviztra® will be available as a once-weekly pen device, offering five strengths, with prices starting at ₹8790/- per month (for 4 weekly doses). The pen device is designed to facilitate simple and precise dosing.
Clinical and Intended Use
Poviztra® is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition.
The product is also indicated to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight. Clinical trials have shown that the semaglutide formulation achieved weight loss of more than 20% in many patients.
Company Statement
Satish Mehta, CEO and Managing Director of Emcure Pharmaceuticals Ltd., stated that India is facing a significant obesity crisis, with nearly 254 million people living with generalised obesity and an additional 351 million with abdominal obesity. The launch of Poviztra® aims to expand access to scientifically validated weight-management solutions.
Source: BSE